Home
Scholarly Works
18F-DCFPyL PET/CT in Oncocytoma
Journal article

18F-DCFPyL PET/CT in Oncocytoma

Abstract

A 76-year-old man with biochemical failure after primary radiotherapy for prostate cancer had no malignant disease detected on Tc-MDP bone scan and diagnostic CT. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed in prostate cancer cells. The PSMA-targeted F-DCFPyL PET/CT demonstrated lymph node disease and photopenic defects in the left kidney associated with a cyst and biopsy-proven oncocytoma. Prostate-specific membrane antigen is expressed in the neovasculature of several solid tumors. It has been reported that PSMA expression is seen in approximately 50% of oncocytoma versus 76% of clear cell renal carcinomas. Biopsy confirmation is needed regardless of F-DCFPyL avidity.

Authors

Li J; Xu R; Kim CK; Bénard F; Kapoor A; Bauman G; Zukotynski KA

Journal

Clinical Nuclear Medicine, Vol. 43, No. 12, pp. 921–924

Publisher

Wolters Kluwer

Publication Date

December 1, 2018

DOI

10.1097/rlu.0000000000002301

ISSN

0363-9762

Contact the Experts team